Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an oral formulation for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative settings.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril (granisetron) is used to prevent nausea and vomiting by acting on the serotonergic pathway.

Chemotherapy‑induced nausea and vomiting: prevents and controls nausea and vomiting in patients receiving emetogenic chemotherapy. Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. Radiation therapy‑induced nausea and vomiting: helps control nausea associated with radiation treatment.

Granisetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhea - Abdominal pain

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmias - Severe allergic reactions such as anaphylaxis - Life‑threatening arrhythmias - Severe constipation or intestinal obstruction

Before prescribing Kytril, clinicians should consider several safety measures. - Cardiac assessment: obtain baseline ECG to evaluate QT interval. - Electrolyte monitoring: correct hypokalemia or hypomagnesemia before use. - Hepatic impairment: use with caution and consider dose adjustment. - Concomitant QT‑prolonging drugs: avoid or monitor closely. - Store at room temperature: keep in the original container, protect from moisture and light.

Granisetron may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of cardiac arrhythmia. - Cisapride: additive effect on QT interval. - Certain antiarrhythmics (e.g., amiodarone): risk of severe arrhythmia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels.

Moderate Interactions (Monitor Closely): - Other antiemetics (e.g., ondansetron): additive serotonergic effects. - CYP3A4 inducers (e.g., rifampin): may reduce granisetron efficacy. - Anticholinergic agents: may exacerbate constipation.